Virginia Osborn1, Babak Givi2, Anna Lee3, Niki Sheth3, Dylan Roden2, David Schwartz3, David Schreiber3. 1. Department of Veterans Affairs, New York Harbor Healthcare System, New York, NY, USA; SUNY Downstate Medical Center, Brooklyn, NY, USA. Electronic address: vwosborn@gmail.com. 2. Department of Veterans Affairs, New York Harbor Healthcare System, New York, NY, USA; New York University Langone Medical Center, New York, NY, USA. 3. Department of Veterans Affairs, New York Harbor Healthcare System, New York, NY, USA; SUNY Downstate Medical Center, Brooklyn, NY, USA.
Abstract
OBJECTIVES: To analyze clinical, treatment and outcome data for patients with salivary ductal carcinoma in a large population-based sample. MATERIALS AND METHODS: The National Cancer Database was queried to identify patients diagnosed with salivary ductal carcinoma between 2004 and 2013. Kaplan Meier and Cox regression analysis were used to assess overall survival (OS) and identify impact of specific variables on OS. RESULTS: A total of 495 patients were identified. The most common site of tumor origin was the parotid (80%). 130 patients (26.3%) presented with early stage (I-II) disease, 257 patients (51.9%) with locoregionally advanced pathologic stage (III-IVB) disease and 41 patients (8.3%) with metastatic disease. The 5year OS for these patients was 79.5%, 40.4% and 0% respectively. At presentation, 46.6% had node positive disease. Surgery was performed in 100% of patients with early stage disease, 98.4% with advanced disease and 90.2% with metastatic disease. Radiation therapy, generally postoperative radiation, was given to 58.5% of patients with stage I-II disease, 71.6% with stage III-IVB disease and 53.7% with metastatic disease. Chemotherapy was utilized in 5.4% of patients with stage I-II disease, 35% with stage III-IVB and 70.7% with metastatic disease. On multivariable analysis, there were no significant differences in OS based on receipt of adjuvant radiotherapy, chemotherapy, or chemoradiotherapy. CONCLUSION: Salivary ductal carcinoma represents an uncommon and aggressive subset of salivary tumors for which current adjuvant treatments do not have a detectable impact on overall survival.
OBJECTIVES: To analyze clinical, treatment and outcome data for patients with salivary ductal carcinoma in a large population-based sample. MATERIALS AND METHODS: The National Cancer Database was queried to identify patients diagnosed with salivary ductal carcinoma between 2004 and 2013. Kaplan Meier and Cox regression analysis were used to assess overall survival (OS) and identify impact of specific variables on OS. RESULTS: A total of 495 patients were identified. The most common site of tumor origin was the parotid (80%). 130 patients (26.3%) presented with early stage (I-II) disease, 257 patients (51.9%) with locoregionally advanced pathologic stage (III-IVB) disease and 41 patients (8.3%) with metastatic disease. The 5year OS for these patients was 79.5%, 40.4% and 0% respectively. At presentation, 46.6% had node positive disease. Surgery was performed in 100% of patients with early stage disease, 98.4% with advanced disease and 90.2% with metastatic disease. Radiation therapy, generally postoperative radiation, was given to 58.5% of patients with stage I-II disease, 71.6% with stage III-IVB disease and 53.7% with metastatic disease. Chemotherapy was utilized in 5.4% of patients with stage I-II disease, 35% with stage III-IVB and 70.7% with metastatic disease. On multivariable analysis, there were no significant differences in OS based on receipt of adjuvant radiotherapy, chemotherapy, or chemoradiotherapy. CONCLUSION:Salivary ductal carcinoma represents an uncommon and aggressive subset of salivary tumors for which current adjuvant treatments do not have a detectable impact on overall survival.
Authors: Ximena Mimica; Marlena McGill; Ashley Hay; Daniella Karassawa Zanoni; Jatin P Shah; Richard J Wong; Alan L Ho; Marc A Cohen; Snehal G Patel; Ian Ganly Journal: Oral Oncol Date: 2019-05-22 Impact factor: 5.337
Authors: Ruta Gupta; Mark J Cowley; Simon A Mueller; Marie-Emilie A Gauthier; James Blackburn; John P Grady; Spiridoula Kraitsek; Elektra Hajdu; Matthias S Dettmer; Jane E Dahlstrom; C Soon Lee; Peter P Luk; Bing Yu; Roland Giger; Sarah Kummerfeld; Jonathan R Clark Journal: Mod Pathol Date: 2020-05-26 Impact factor: 7.842
Authors: Kyriakos Chatzopoulos; Andrea R Collins; Sotiris Sotiriou; Michael G Keeney; Daniel W Visscher; Michael Rivera; David J Schembri-Wismayer; Jean E Lewis; Patricia T Greipp; William R Sukov; Ashish V Chintakuntlawar; Katharine A Price; Joaquin J Garcia Journal: Head Neck Pathol Date: 2020-04-29
Authors: Ann-Jean C C Beck; Peter J F M Lohuis; Abrahim Al-Mamgani; Laura A Smit; Willem M C Klop Journal: Eur Arch Otorhinolaryngol Date: 2018-05-21 Impact factor: 2.503
Authors: Victor T G Lin; Lisle M Nabell; Sharon A Spencer; William R Carroll; Shuko Harada; Eddy S Yang Journal: J Natl Compr Canc Netw Date: 2018-10 Impact factor: 11.908
Authors: Eline Boon; Miranda Bel; Wim van Boxtel; Winette T A van der Graaf; Robert J J van Es; Simone E J Eerenstein; Robert J Baatenburg de Jong; Michiel W M van den Brekel; Lilly-Ann van der Velden; Max J H Witjes; Ann Hoeben; Stefan M Willems; Elisabeth Bloemena; Laura A Smit; Sjoukje F Oosting; Marianne A Jonker; Uta E Flucke; Carla M L van Herpen Journal: Int J Cancer Date: 2018-03-23 Impact factor: 7.396